Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 11—November 2022
Research

Prevalence of Histoplasmosis among Persons with Advanced HIV Disease, Nigeria

Rita O. OladeleComments to Author , Iriagbonse I. Osaigbovo, Alani S. Akanmu, Olukemi A. Adekanmbi, Bassey E. Ekeng, Yahaya Mohammed, Mary A. Alex-Wele, Mark O. Okolo, Stephen T. Ayanbeku, Uchechukwu S. Unigwe, Iorhen E. Akase, Alali Dan-Jumbo, Dennis Israelski, David W. Denning, Alessandro C. Pasqualotto, and Tom Chiller

Author affiliations: Lagos University Teaching Hospital, Lagos, Nigeria (R.O. Oladele, I.E. Akase); University of Benin Teaching Hospital, Benin City, Nigeria (I.I. Osaigbovo); University of Lagos, Lagos, Nigeria (R.O. Oladele, A.S. Akanmu); University of Ibadan, Ibadan, Nigeria (O.A. Adekanmbi); University of Calabar Teaching Hospital, Calabar, Nigeria (B.E. Ekeng); Usmanu Danfodiyo University College of Health Sciences, Sokoto, Nigeria (Y. Mohammed); University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria (M.A. Alex-Wele); University of Jos, Jos, Nigeria (M.O. Okolo); Federal Medical Centre, Bida, Nigeria (S.T. Ayanbeku); University of Nigeria Teaching Hospital, Enugu, Nigeria (U.S. Unigwe); Rivers State University Teaching Hospital, Port Harcourt (A. Dan-Jumbo); Gilead Sciences International Medical Affairs, Global Patient Solution, San Francisco, California, USA (D. Israelski); University of Manchester, Manchester, UK (D.W. Denning); Universidade Federal de Ciencias da Saude de Porto Alegre, Porto Alegre, Brazil (A.C. Pasqualotto); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (T. Chiller)

Main Article

Table 4

Clinical features of participants in study of prevalence of histoplasmosis among persons with AIDS, Nigeria

Clinical features No. (%) participants No. histoplasmosis urine Ag+/total no. (%) p value
Fever 0.602*
N 290 (29.4) 20/290 (6.9)
Y
 698 (70.6)
 56/698 (8)
Cough 0.631*
N 437 (44.2) 36/437 (8.2)
Y
 551 (55.8)
 40/551 (7.3)
Weight loss 0.882*
N 200 (20.2) 16/200 (8.0)
Y
 788 (79.8)
 60/788 (7.6)
Diarrhea 0.055*
N 733 (74.2) 49/733 (6.7)
Y
 255 (25.8)
 27/255 (10.6)
Hepatomegaly 0.722†
N 944 (95.5) 72/944 (7.6)
Y
 44 (4.5)
 3/44 (6.8)
Central nervous system symptoms 0.166†
N 875 (88.6) 71/875 (8.1)
Y
 113 (11.4)
 5/113 (4.4)
Splenomegaly 0.307†
N 955 (96.7) 75/955 (7.9)
Y
 33 (3.3)
 1/33 (3.0)
Lymphadenopathy 0.163*
N 856 (86.6) 70/856 (8.2)
Y
 132 (13.4)
 6/132 (4.5)
Cutaneous lesions 0.329*
N 886 (89.7) 71/886 (8.0)
Y
 102 (10.3)
 5/102 (4.9)
Oral mucosal lesions/ulcers 0.562†
N 920 (93.1) 72/920 (7.8)
Y
 68 (6.9)
 4/68 (5.9)
GeneXpert 0.588†
Negative 871 (88.2) 67/871 (7.7)
Positive 117 (11.8) 9/117 (7.7)

*Fisher exact test. †Pearson χ2 test.

Main Article

Page created: September 07, 2022
Page updated: October 21, 2022
Page reviewed: October 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external